Cancer latest info, news, treatment, advice- Mainstream and alternative cancer cures

A large-scale long term study taking up to ten years and involving older American men found that Vitamin E and Vitamin C were no different to placebo in protecting against cancer. The researchers presented their findings at the 7th Annual International Conference on Frontiers in Cancer Prevention Research hosted by the American Association for Cancer Research (AACR) and taking place in National Harbor, Maryland, this week.

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company and the U.S. Food and Drug Administration (FDA) have reached agreement on the design of a phase 3 registration trial for thymalfasin as a potential treatment for stage IV melanoma. Based on the FDA's review, the agency agrees that the design and planned analysis of SciClone's study adequately addresses the objectives necessary to support a regulatory submission.

The following is a summary of efforts and grants that seek to reduce racial and ethnic health disparities. Alaska Native Tribal Health Consortium: The

Propelled by advances in molecular biology, the treatment of colorectal cancer is on the verge of dramatic change and a promising future as innovative vaccines will replace chemotherapy. According to a new report from Kalorama Information, "Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis," this market, lead by OncoVAX, is poised for unprecedented growth, creating countless opportunities for market participants.

Plymouth Hospitals NHS Trust has been chosen to co-ordinate the national programme for the training of existing consultants in advanced keyhole surgery for the treatment of bowel cancer. The Department of Health has appointed Consultant General Surgeon, Mr Mark Coleman as the National Clinical Lead for the Laparoscopic Colorectal Cancer Surgery Training Programme.

Boehringer Ingelheim has marked a new milestone within its rapidly expanding oncology portfolio with the announcement today that the company has progressed another of its oncology compounds into pivotal phase III clinical development.

A new piece of medical technology unveiled at the National Physical Laboratory (NPL) will help improve the success rates of radiotherapy cancer treatments. The new clinical electron linear accelerator (linac) will help ensure patients are treated with accurate doses of radiation. Radiotherapy treats cancer, by using ionising radiation such as high-energy X-rays or electron beams, to destroy cancer cells.

Cytopia Limited (ASX:CYT) has commenced dosing patients in its Phase Ib/II study of CYT997, the company's novel vascular-disrupting anticancer agent, to treat glioblastoma multiforme (GBM), an aggressive brain cancer. The GBM clinical trial is the company's first Phase II efficacy study in highly vascular, solid tumour indications and the first time CYT997 is being investigated in a tumour of the central nervous system.

Teens continue to put themselves at unnecessary risk of skin cancer by spending excessive time in the sun and forgetting to protect themselves, according to new Cancer Council research. Findings from the Cancer Council's National Sun Protection Survey released today show teens spend an average of two hours (1hr 51mins) in the sun during peak UV, with almost a third who get sunburnt saying they "forgot" to protect themselves.

In the November 15th issue of G&D, Dr. Kenneth Dorshkind and colleagues at the David Geffen School of Medicine (UCLA) have identified two genes - p16(Ink4a) and Arf - that sensitize lymphoid progenitor cells to the effects of aging, and confer resistance to leukemogenesis. Hematopoiesis (the development of blood cells) entails two main pathways: myelopoiesis (the formation of the red and white myeloid cells) and lymphopoiesis (the formation of B- and T-cells).

The link between the PSA (prostate-specific antigen) blood test and the detection of prostate cancer is well-established. In new findings released publicly for the first time today, Australian and New Zealand researchers have demonstrated how two serial measures of PSA can be used to accurately predict a patient's prognosis when prostate cancer returns after attempted cure.

European advocacy and support groups working with patients who have some of the rarest cancers have agreed to form a collaborative association. Sarcoma Patients EuroNet (SPAEN) will start work in January 2009 with the aim of extending information services, patient support and advocacy so that patients across the whole of Europe can benefit.

Veridex, LLC announced today that the technology used in the CellSearch® System to measure circulating tumor cells (CTCs) was ranked as the top medical innovation for 2009 by the Cleveland Clinic, a leading multispecialty academic medical center. The ranking is based on technologies likely to have a significant impact on health care next year.

UroToday.com - Can we meaningfully separate inflammatory pseudotumor (a term used since 1937 1 from inflammatory myofibroblastic tumor (IMT, a term introduced in 1990 for lung lesions 2 and from sarcoma? The oldest large series of 38 such cases in the urinary bladder divided most of them into 17 pseudotumors and 13 sarcomas 3.

A $3.8 million Innovator Award, from the Department of Defense, is being granted over five years to an internationally renowned cancer researcher at the University of California, Santa Barbara. Erkki Ruoslahti, recipient of the award, is known for his innovative, interdisciplinary research. "This is a special award because there are only four of them," said Ruoslahti. "I am very happy at being chosen." The award is designed to further his current research.

UroToday.com - The molecular mechanisms underlying development of androgen-independent growth of prostate cancer are largely unknown, and no effective therapies for hormone-refractory prostate cancer exist at present.

An intra cellular pathway not previously linked to breast cancer is driving a sub-type of the disease that is highly lethal and disproportionately over-represented in African American women. The pathway regulates how cells identify and destroy proteins and represents a class of genes called proteasome targeting complexes. The work shows that basal cancer cells degrade the tumor suppressor gene p27 by making a new type of proteasome targeting complex.

There has been much speculation over the last few years about whether cell phones increase the risk of developing a brain tumor. Research has not conclusively answered this question, which has left consumers confused. The majority of studies that have been published in scientific journals do not have sufficient evidence to show that cell phones increase the risk of brain tumors.

Using a new approach that combines scientific technologies to hunt down genetic changes involved in cancer, researchers have discovered 13 tumor suppressor genes that, when mutated, can lead to liver cancers. Twelve of those genes had never been linked to cancer before, according to the report published online in the journal Cell, a Cell Press publication, on November 13th.

The finding: Researchers at the University of Michigan Comprehensive Cancer Center have found a genetic marker that controls an enzyme present in aggressive and metastatic cancer. The study suggests an absence of microRNA-101 is related to high expression of the protein EZH2, which was previously shown to be active in metastatic cancers. MicroRNA's are molecules that help regulate gene expression.